Maturu Paramahamsa, Jones Devin, Ruteshouser E Cristy, Hu Qianghua, Reynolds Joseph M, Hicks John, Putluri Nagireddy, Ekmekcioglu Suhendan, Grimm Elizabeth A, Dong Chen, Overwijk Willem W
Department of Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1010, Houston, TX 77030, USA; Department of Pediatrics, Section of Neonatology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX 77030, USA.
Department of Genetics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1010, Houston, TX 77030, USA.
Neoplasia. 2017 Mar;19(3):237-249. doi: 10.1016/j.neo.2016.07.009.
Wilms' tumors (WT), which accountfor 6% of all childhood cancers, arise from dysregulated differentiation of nephrogenic progenitor cells from embryonic kidneys. Though there is an improvement in the prognosis of WT, still 10% of patients with WT die due to recurrence. Thus more effective treatment approaches are necessary. We previously characterized the inflammatory microenvironment in human WT and observed the robust expression of COX-2. The aim of this study was to extend our studies to analyze the role of COX-2 pathway components in WT progression using a mouse model of WT. Herein, COX-2 pathway components such as COX-2, HIF1-α, p-ERK1/2, and p-STAT3 were upregulated in mouse and human tumor tissues. In our RPPA analysis, COX-2 was up-regulated in M15 cells after Wt1 gene was knocked down. Flow cytometry analysis showed the increased infiltration of immune suppressive inflammatory cells such as pDC's and Treg cells in tumors. The chemotactic chemokines responsible for the infiltration of these cells were also induced in CCR5 and CXCR4 dependent manner respectively. The immunosuppressive cytokines IL-10, TGF-β, and TNF-α were also up-regulated. Furthermore, more pronounced Th2 and Treg induced cytokine response was observed than Th1 response in tumors. Basing on all these evidences it is speculated that COX-2 pathway may be a beneficial target for the treatment of WT. It may be most effective as an adjuvant therapy together with other inhibitors. Thus, our current study provides a good rationale for initiating animal studies to confirm the efficacy of COX-2 inhibitors in decreasing tumor cell growth in vivo.
肾母细胞瘤(WT)占儿童所有癌症的6%,起源于胚胎肾源性祖细胞分化失调。尽管WT的预后有所改善,但仍有10%的WT患者因复发而死亡。因此,需要更有效的治疗方法。我们之前对人类WT中的炎症微环境进行了表征,并观察到COX-2的强烈表达。本研究的目的是扩展我们的研究,使用WT小鼠模型分析COX-2通路成分在WT进展中的作用。在此,COX-2、HIF1-α、p-ERK1/2和p-STAT3等COX-2通路成分在小鼠和人类肿瘤组织中上调。在我们的RPPA分析中,Wt1基因敲低后,M15细胞中COX-2上调。流式细胞术分析显示,肿瘤中免疫抑制性炎症细胞如浆细胞样树突状细胞(pDC)和调节性T细胞(Treg)的浸润增加。负责这些细胞浸润的趋化因子也分别以CCR5和CXCR4依赖性方式被诱导。免疫抑制细胞因子IL-10、TGF-β和TNF-α也上调。此外,在肿瘤中观察到Th2和Treg诱导的细胞因子反应比Th1反应更明显。基于所有这些证据推测,COX-2通路可能是WT治疗的一个有益靶点。作为与其他抑制剂联合的辅助治疗可能最有效。因此,我们目前的研究为启动动物研究以证实COX-2抑制剂在体内降低肿瘤细胞生长的疗效提供了良好的理论依据。